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Abstract
With the trend of an increasing aged population worldwide, Alzheimer’s disease (AD), an age-related neurodegenerative
disorder, as one of the major causes of dementia in elderly people is of growing concern. Despite the many hard efforts
attempted during the past several decades in trying to elucidate the pathological mechanisms underlying AD and putting
forward potential therapeutic strategies, there is still a lack of effective treatments for AD. The efficacy of many potential
therapeutic drugs for AD is of main concern in clinical practice. For example, large bodies of evidence show that the anti-
tumor histone deacetylase (HDAC) inhibitor, suberoylanilidehydroxamic acid (SAHA), may be of benefit for the treatment of
AD; however, its extensive inhibition of HDACs makes it a poor therapeutic. Moreover, the natural flavonoid, curcumin, may
also have a potential therapeutic benefit against AD; however, it is plagued by low bioavailability. Therefore, the integrative
effects of SAHA and curcumin were investigated as a protection against amyloid-beta neurotoxicity in vitro. We
hypothesized that at low doses their synergistic effect would improve therapeutic selectivity, based on experiments that
showed that at low concentrations SAHA and curcumin could provide comprehensive protection against Ab25–35-induced
neuronal damage in PC12 cells, strongly implying potent synergism. Furthermore, network analysis suggested that the
possible mechanism underlying their synergistic action might be derived from restoration of the damaged functional link
between Akt and the CBP/p300 pathway, which plays a crucial role in the pathological development of AD. Thus, our
findings provided a feasible avenue for the application of a synergistic drug combination, SAHA and curcumin, in the
treatment of AD.
Citation: Meng J, Li Y, Camarillo C, Yao Y, Zhang Y, et al. (2014) The Anti-Tumor Histone Deacetylase Inhibitor SAHA and the Natural Flavonoid Curcumin Exhibit
Synergistic Neuroprotection against Amyloid-Beta Toxicity. PLoS ONE 9(1): e85570. doi:10.1371/journal.pone.0085570
Editor: Wei-Guo Zhu, Peking University Health Science Center, China
Received September 28, 2013; Accepted November 30, 2013; Published January 7, 2014
Copyright:  2014 Meng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Heilongjiang Province Foundation for Returnees (LC2009C13) and Foundation of Heilongjiang Educational Committee
(12521z019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yinazhlu@163.com (YZ); jianglihong2006@163.com (LJ)
. These authors contributed equally to this work.
Introduction
Alzheimer’s disease (AD) is the main cause of dementia [1]. It is
pathologically defined as an age-related progressive neurodegen-
erative disorder and characterized by the extracellular accumula-
tion of amyloid-beta (Ab) plaques [2], the intracellular aggregation
of neurofibrillary tangles (NFTs) formed by hyperphosphorylated
tau protein [3]. Although there are many medicines available for
the treatment of AD in the clinic, such as the acetylcholinesterase
inhibitor, rivastigmine, and the low-affinity NMDA (N-methyl-d-
aspartate) receptor antagonist, memantine, neither one of these
can really treat the underlying causes of AD except for just
rendering some modest symptomatic improvement. With the
trend of an increasing aged population worldwide and due to the
lack of effective treatments, it is pessimistically estimated that AD
might overwhelm the society and health-care systems in the near
future [4].
Current amyloid-b-directed therapeutics were thought of as the
most promising strategy for AD; however, they have been failing
Phase III clinical trials, this leads to doubt amyloid-b as the leading
player in the amyloid cascade hypothesis, which has profoundly
affected the AD field for two decades [5,6]. Some scholars suggest
that the current amyloid cascade hypothesis is still correct but that
some modification is needed [4]. Amyloid-b is considered as a
trigger for the pathogenesis of AD but it is not the major disease
driver. Taken together, amyloid-b-directed therapeutics fail to
undermine the complexity of AD pathology which suggests that
alternative therapeutic strategies should be proposed with the
premise of an in-depth understanding of AD pathology and
treatment response.
Recent gene expression and functional studies have demon-
strated that significant chromosomal alterations of histone
acetylation and DNA methylation might play a vital role in
initiating the pathogenesis of AD [7–9]. In human cells, histone
acetyltransferases (HATs) and histone deacetylases (HDACs)
catalyze histone acetylation and deacetylation, respectively; thus,
the vital role in adjusting histone acetylation to healthy levels, and
targeting AD-associated abnormal histone acetylation make
HDACs rational therapeutic targets [10]. Actually, it has been
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experimentally validated that the HDAC inhibitor, suberoylani-
lidehydroxamic acid (SAHA), truly improved memory and
cognition in an AD animal model, suggesting it as a promising
treatment for AD [11]. However, SAHA is classified as a non-
selective HDAC inhibitor due to its extensive targeting of HDAC
proteins including HDAC1, HDAC2, HDAC3, HDAC6, and
HDAC8 [12]. This leads to widespread worries by research
scholars about the therapeutic selectivity of SAHA as a treatment
for AD [13,14].
Based upon the confirmatory conclusion that the therapeutic
selectivity of one drug could be significantly improved when in a
synergistic drug combination [15], we proposed here that SAHA,
as an alternative treatment for AD, is feasible, but only if a
clinically available drug could be found to act synergistically with
it. With this working hypothesis, we examined whether SAHA and
the natural flavonoid, curcumin, could synergistically protect
against Ab-induced neuronal apoptosis in PC12 cells. The latter
has been shown to protect against neuronal injuries [16]. In the
present study, we sought to validate the synergistic neuroprotec-
tion effect of SAHA and curcumin. Our in vitro experiments
indicated a potent synergistic neuroprotection effect exists when
SAHA is in combination with curcumin at low concentration
levels. Furthermore, we also attempted to clarify the synergistic
mechanism by integrating public resources for performing network
analysis of global gene expression in AD [7]. Specifically, our
results collectively indicated that the CBP/p300 signaling pathway
might play a dominant role in the progression of AD. However,
further dissection of protein connectivity suggested that the activity
of Akt was necessarily required for functional execution of CBP/
p300 in tuning gene transcription. We further confirmed that the
interaction between Akt and the CBP/p300 signaling pathway was
vital to the repair of Ab-induced neuronal injury during co-
treatment of SAHA and curcumin.
In the present study, we validated the synergistic neuroprotec-
tion of SAHA and curcumin. The possible mechanism underlying
the synergistic action was also revealed. In addition, since both
SAHA and curcumin are commercially available, this makes our
proposed synergistic drug therapeutic strategy for AD treatment
accessible. Overall, our finding provides a rationale avenue for
clinical implementation of SAHA in selectively treating AD in the
current clinical context.
Materials and Methods
Cell Culture and Treatment
Rat pheochromocytoma PC12 cells were originally obtained
from Chinapeptides Co., Ltd. PC12 neuron cells were cultured in
DMEM-F12 containing 7% FBS, 1% penicillin, and 1%
streptomycin at 37uC. Before the drug treatment, cells were
Figure 1. Effect of SAHA and curcumin on cell viability of PC12 cells. A. PC12 cells were treated with different concentrations of Ab25–35
(n = 5). *, p,0.05; ***, p,0.001 vs Ctrl. B. PC12 cells were treated with different concentrations of SAHA (n= 5). *, p,0.05; ***, p,0.001 vs Ctrl. C. PC12
cells were treated with different concentrations of curcumin (n = 5). *, p,0.05; ***, p,0.001 vs Ctrl. D. MTT assay was performed to detect cell viability
after treating with SAHA and curcumin against Ab25–35-induced cytotoxicity in PC12 cells (n = 5). ***, p,0.001 vs Ctrl; **, p,0.01 vs Ab25–35.
doi:10.1371/journal.pone.0085570.g001
Figure 2. Effect of SAHA and curcumin on neuronal integrity
and oxidative stress. A. Result of AO/EB staining. S: SAHA; C:
curcumin. B. Result of SOD content measurement. ***, p,0.001 vs Ctrl;
#, p,0.05; ##, p,0.01, ###, p,0.001, vs Ab25–35.
doi:10.1371/journal.pone.0085570.g002
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cultured in serum-free medium for 12 h. SAHA (1 mM) and
curcumin (5 mM) were then added alone or together 1 h prior to
adding the Ab25–35 (20 mM) treatment. The cells were then
incubated for another 24 h in a humidified incubator in the
presence of 95% O2 and 5% CO2.
MTT Assay
MTT assay was used to measure the viability of PC12 cells.
Briefly, PC12 cells were plated in a 96-well plate in DMEM-F12
with 7% FBS. After culturing in serum-free DMEM-F12 for 12 h,
Ab25–35 (20 mM) alone or in combination with SAHA,curcumi-
n,or SAHA+curcumin were added to the medium. Twenty-four
hours later, PC12 cells were incubated with 10 mL MTT (Roche,
0.5 mg/ml) at 37u for 4 h, and then the crystals were dissolved
with 150 mL DMSO. Absorbance at 570 nm was detected by a
spectrophotometer (TECAN Infinite M200, Switzerland).
Acridine Orange/ethidium Bromide (AO/EB) Staining
To detect the impact of SAHA (1 mM) and curcumin (5 mM) on
Ab25–35 (20 mM) mediated cell apoptosis, the cultured PC12 cells
were washed with PBS and then incubated with 100 mg/mL of
AO and EB (Sigma Aldrich, USA) for 5 min. Normal and
apoptotic cells were observed under a fluorescence microscope
equipped with a CCD digital camera (Nikon Corporation, Japan).
Superoxide Dismutase Activity (SOD) Measurement
The activity of SOD in PC12 cells was measured using the SOD
Detection kit (Nanjing Jiancheng Bioengineering Institute, China).
Following the manufacturer’s instruction, the results were deter-
mined at 550 nm and are expressed as unit per mgprot.
TdT-mediated dUTP Nick End Labeling (TUNEL) Staining
For apoptosis analysis, DNA fragmentation of PC12 cells was
measured with an in situ Cell Death Detection Kit (Roche
Diagnostics Corporation, Indianapolis, IN, USA), according to the
manufacturer’s instructions. Followed by TUNEL staining, PC12
cell nuclei were counterstained with DAPI (Sigma-Aldrich, St
Louis, MO, USA). With a fluorescence microscope (Nikon 80i,
Japan), TUNEL positive PC12 cells were counted in 5 randomly
selected fields (2006magnification), respectively, and the average
rate of apoptotic cells was calculated.
Western Blot Analysis
Protein samples extracted from the PC12 cells were used for
immunoblotting analysis. Briefly, samples were fractionated by
SDS-PAGE (10% polyacrylamide gels), transferred to nitrocellu-
lose membrane (Millipore, Bedford, MA, USA) and incubated
with primary antibodies against Akt (Cell Signaling Technology,
Inc. USA), p(Ser 473)-Akt (Cell Signaling Technology, Inc. USA),
cleaved caspase 3 (Cell Signaling Technology, Inc. USA) and b-
actin (KangchengInc, China) at 4uC overnight. The membranes
were washed and incubated with secondary antibodies for 1 hour
at room temperature. Finally, the bands were quantified with the
Odyssey v1.2 software by measuring intensity (area6OD); b-actin
was used as the internal control.
Figure 3. Effect of SAHA and curcumin on cell apoptosis of PC12 cells. A. Apoptotic cells were detected by TUNEL assay. Cells were stained
with TUNEL positive nuclei (green) and nuclei of PC12 cells (blue). B. The percentage of TUNEL positive cells was determined (n = 5). ***, p,0.001 vs
Ctrl; **, p,0.01 vs Ab25–35. Ctrl: the control group. C. Western blot of cleaved caspase 3 (n = 3). ***, p,0.001 vs Ctrl; **, p,0.01 vs Ab25–35. Ctrl: the
control group; CASP3: caspase 3.
doi:10.1371/journal.pone.0085570.g003
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Gene Expression Correlation Analysis
The gene microarray dataset (accession number: GSE1297) was
retrieved from the Gene Expression Omnibus (GEO) database [7].
The 22 disease hippocampus samples were divided into three
groups according to the stages of AD. The gene expression value
was only accepted if detected as ’present’ or ’marginal’ on at least
16 chips. The likelihood of the normal distribution of the values of
MiniMental Status Examination (MMSE) and neurofibrillary
tangle (NFT) scores was assessed using the D’Agostino & Pearson
omnibus normality test. MMSE scores were of normal distribution
(p= 0.183), so where the NFT scores after square root transfor-
mation (p= 0.795). Pearson linear correlation assessment was
applied for the median-normalized expression values (log2) of each
gene with MMSE score and the square root of NFT score,
respectively at different stages of AD. The Benjamini and
Hochberg method of multiple testing [17] was then applied to
adjust the p-values for genes if values of the square of correlation
coefficient R2 were more than 0.30 for the MMSE score or for the
square root of NFT score at any disease stage. Significant AD
relation was only accepted when the adjusted p-value was less than
0.05.
Network Topology Calculation
By retrieving experimentally validated PPIs [18], Cytoscape
[19] generated a human hippocampus-specific PPI network
(hHPIN) for the proteins expressed in human hippocampus [20].
Single nodes and small network components were removed and so
were the self-loop edges. The pruning was done in order to analyze
the giant component of the network. The topological parameters,
degree and betweenness centrality were calculated [21] to identify
hubs (degree .50) and nodes that exerted extensive control over
PPIs (betweenness centrality .561024).
Gene Ontology (GO) Analysis
The DAVID functional annotation clustering tool was applied
to detect significantly over-represented biological processes for the
up- and down-regulated AD-related genes, respectively (Enrich-
ment Score .2.0) [22]. All tool options were set as default except
when the threshold of Ease Score was 0.05 and the number of
genes was more than ten. As the gradual change of disease-related
processes reflected the evolution trajectory of the AD pathology to
a certain extent, genes of abnormal expression were counted at
different disease stages for each process.
GenePro and Expression Distance Analyses
Different proteins can jointly participate in one process. Here,
we hypothesize that two processes might be related functionally if
experimental evidence suggested that protein A in a process
interacted with protein B in another process. GenePro was applied
to investigate the functional link between AD-related processes
[23]. More PPIs might mean closer functional link between two
processes. A geometry distance formula of 2 points in a three-space
was applied to calculate the gene expression distance between
different processes. Simply, to a given process the percentages of its
process genes at early-, medium- and late-stage of AD were
symbolized as the three-space point coordinate x, y and z,
respectively. Short gene expression distances indicated a coordi-
nated gene expression trend was adopted by two processes.
Figure 4. Changes of Akt phosphorylation in PC12 cells after SAHA, curcumin or SAHA+curcumin treatment. A. Representative western
blot of the p-Akt (Ser 473) protein expression with SAHA treatment (n = 3). **, p,0.01 vs Ctrl. B. Representative western blot of the p-Akt (Ser 473)
protein expression with curcumin treatment (n = 3). **, p,0.01 vs Ctrl. C. Representative western blot of the p-Akt (Ser 473) protein expression with
co-treatment of SAHA and curcumin (n = 3) to the PC12 cells (n = 3). *, p,0.05 vs Ctrl; **, p,0.01 vs Ab25–35; Ctrl: the control group.
doi:10.1371/journal.pone.0085570.g004
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Statistical Analysis
All data are expressed as means 6 SEM. Statistical analysis was
performed using one-way ANOVA followed by correction for
multiple testing using Bonferroni’s method. Differences were
considered as statistically significant when p,0.05.
Results
The Combination of SAHA and Curcumin Improved
Cellular Viability of Ab-treated PC12 Cells
Increasing concentrations of Ab25–35, SAHA, and curcumin
alone were able to induce obvious cytotoxicity in PC12 cells as
indicated by the MMT assay (Figure 1A–C). The respective
concentrations of SAHA and curcumin were optimally selected at
1 and 5 mM for the following evaluation of their potential
synergistic effect against Ab25–35-induced neuronal injury. Despite
that SAHA at 1 mM and curcuminat 5 mM showed no apparent
cytotoxicity in PC12 cells, we did not observe an obvious
improvement in cell viability after using SAHA or curcumin
treatment alone (Figure 1D). This result was further confirmed
because the selected concentrations of SAHA and curcumin were
too low to obtain any acceptable neuronal cell restoration from
Ab25–35-induced damage as AO/EB staining and SOD measure-
ment indicated (Figure 2).
Interestingly, we found that a significant relief from Ab25–35-
induced neuronal injury could be clearly achieved by applying a
combination of 1 mM SAHA and 5 mM curcumin (p,0.01) in
PC12 cells, implying potential synergy (Figure 1D). In addition to
improving neuronal viability, co-treatment of SAHA and curcu-
min could also successfully restore the structural integrity of the
neuronal cells and intracellular oxidative stress environment that
was caused by excessive deposition of Ab (Figure 2). This finding
definitely suggests that the monotherapy of the anti-tumor HDAC
inhibitor SAHA is not a rational treatment avenue for reversing
AD pathology due to poor therapeutic specificity at a low dose and
significant neurotoxicity at a high dose. However, co-treatment of
SAHA and curcumin could be a better choice as a result of the
synergistic protection against Ab-mediated decline in neuronal
function.
SAHA and Curcumin Synergistically Inhibit Ab-induced
Cellular Apoptosis in PC12 Cells
The results of TUNEL staining assay and Western blot analysis
of cleaved caspase 3 further validated a synergistic protective effect
exists between SAHA and curcumin against Ab25–35-mediated cell
Figure 5. Illustration of gene expression correlation analysis with CREBBP (MMSE score) and EP300 (NFT score) as example. MMSE
score:MiniMental Status Examination score; NFT score: neurofibrillary tangle score. Normalized value: the median-normalized gene expression value
(log2).
doi:10.1371/journal.pone.0085570.g005
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apoptosis in PC12 cells (Figure 3). Similarly, we found that co-
treatment of SAHA and curcumin, but not SAHA or curcumin
alone, provided an obvious anti-apoptotic effect against Ab25–35-
induced neuronal injury. The result of the TUNEL staining assay
was consistent with that observed in AO/EB staining (Figure 2A).
It has been reported that inhibition of Akt activity could induce
Figure 6. Results of network topology calculation for AD-related genes. A. Statistical result of R2 for hub-encoding genes (degree .50) at
different thresholds. B. Statistical result of R2 for genes encoding proteins of high betweenness centrality (betweenness centrality .561024) at
different thresholds. C. Strong binomial correlation was found between the topological parameters degree and betweenness centrality (R = 0.849).





2 with MMSE score at early-, medium-, and





2 with square root of NFT score at early-, medium-, and late-stage of AD, respectively.
doi:10.1371/journal.pone.0085570.g006
Table 1. Significant over-represented biological processes in AD.
Gene expression Processes (ES, sum of genes) Early (%a) Medium (%) Late (%)
Up-regulated Regulation of transcription (3.38, 99) 40 (27.0%) 54 (39.7%) 48 (37.5%)
Histone acetylation (2.28, 19) 7 (4.7%) 9 (6.6%) 10 (7.8%)
RNA processing and transport (2.20, 30) 11 (7.4%) 16 (11.8%) 11 (8.6%)
Down-regulated Protein transport (4.04, 69) 32 (21.6%) 19 (14.0%) 24 (18.8%)
Glycolysis (3.05, 13) 9 (6.1%) 3 (2.2%) 3 (2.3%)
Cellular respiration (2.20, 37) 14 (9.5%) 12 (8.8%) 13 (10.2%)
Endocytosis (2.12, 26) 16 (10.8%) 7 (5.1%) 9 (7.0%)
Regulation of protein ubiquitination (2.02, 38) 19 (12.8%) 16 (11.8%) 10 (7.8%)
Significant over-represented biological processes in AD. ES: Enrichment Score; a: the relative percentage proportion of the number of genes in each process
was calculated at early-, medium-, late-stage of AD, respectively.
doi:10.1371/journal.pone.0085570.t001
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neuronal apoptosis [24]. Thus, we would expect to see an increase
in Akt activity in the presence of SAHA and curcumin. In our
study, we validated an apparent improvement of Akt activity and a
decrease in apoptosis by the novel SAHA and curcumin
combination and that this improvement might be through the
synergistic enhancement of p-Akt1 activity (Figure 4).
Both CREBBP and EP300 Maintain Significantly Correlated
Expression as AD Evolves
Gene expression correlation analysis was performed to obtain
the AD gene profiles of different disease stages. The genes
CREBBP and EP300 were used as examples for the methodology
illustration (Figure 5). CREBBP and EP300 genes have been
reported to be associated with AD and their expression
significantly correlated with MMSE score and the square root of
NFT score, respectively (R2.0.30, adjusted p-value ,0.05). We
identified a total of 862 AD-related protein-encoding genes. More
AD-related genes were significantly correlated with the square root
of the NFT score (n = 329) than with the MMSE score (n = 115) at
the early-stage of AD. This finding was consistent with the fact that
there is little MMSE decline in patients with early AD [25].
After calculating the topological parameter degree for all nodes
in the hHPIN (6829 nodes and 40478 edges), we found that there
were only several hub-encoding genes maintaining significant
expression correlation with MMSE score or with the square root
of NFT score during the progression of AD (Figure 6A). We
focused on hub-encoding genes due to their vital roles in cellular
functions [26,27]. Despite these were a small number of genes,
aberrant expression of these hub genes suggested that their
greatest responsibility is the initiation and evolution of AD
pathology. Furthermore, due to the potential critical roles of
proteins of high betweenness centrality in AD [28], we also
assessed the AD-related genes that encoded proteins of high
betweenness centrality using gene expression correlation
(Figure 6B). A strong binomial correlation was found between
degree and betweenness centrality (Figure 6C). The MMSE score
was responsible for only one gene that encoded hub of high
betweenness centrality, EP300 (R2e-m = 0.50, R
2
l-m = 0.31), and
the NFT score for another three genes including CREBBP (R2m-
n = 0.34, R
2
l-n = 0.36), EIF6 (R
2
e-n = 0.47, R
2
m-n = 0.32), and
NEDD8 (R2e-n = 0.42, R
2
m-n = 0.31). CREBBP and EP300
encoded two hub proteins CBP (CREB binding protein) and
p300 (E1A binding protein p300), respectively. Our finding
implies that the CBP/p300 signaling pathway might play a
pivotal role in the progression of AD [13].
Restoring a Functional Link between Crucial AD-related
Processes may Benefit AD
GO analysis revealed that eight processes were significantly
over-represented in AD pathology (Table 1). The emergence of
regulation of transcription, histone acetylation, and RNA process-
ing and transport suggested the continuous adjustment of cellular
transcriptional behaviors; whereas, involvement of glycolysis,
cellular respiration, and endocytosis suggested gradual weakening
of cellular energy supply and neuronal functions. We also disclosed
the functional association between AD-related processes by
applying GenePro (Figure 7). Two up-regulated processes,
regulation of transcription and histone acetylation, were the most
Figure 7. Results of GenePro and expression distance analyses. The AD-related processes of up- and down-regulation were distinguished
using red and green border colors. If gene expression distance was less than 0.20, two nodes representing AD-related processes were connected with
edge by solid line. If PPIs was more than 20, them were connected with edge by dashed line.
doi:10.1371/journal.pone.0085570.g007
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closely interacted [58 protein-protein interactions (PPIs)] among
all of the process pairs, followed by the down-regulated process
pair, protein transport and regulation of protein ubiquitination (40
PPIs). Strong functional links between the above process pairs
suggested that their process genes were functionally complemen-
tary to each other. The presence of a high number of PPIs
between the up-regulated process of regulation of transcription
and the two down-regulated processes, protein transport (33 PPIs)
and regulation of protein ubiquitination (22 PPIs), implies there is
an impaired functional connection between them during AD.
Aberrant gene expression reflected continuous alteration of
processes as AD developed. Gene expression distance analysis
measured whether two AD-related processes would likely be co-
expressed during AD. Results indicated that gene expression
orientation really produced an obvious impact on gene co-
expression (Figure 7). More importantly, it strongly suggested the
remarkable imbalance of the up- and down-regulated AD-related
processes. Uncoordinated gene expression may more seriously
affect the processes that are closely functionally, especially when
their links are dependent on a large number of PPIs. Uncoordi-
Figure 8. Network visualization of interactions between proteins encoded by up-regulated AD process genes (red triangle nodes)
and those encoded by down-regulated AD process genes (light green rectangle nodes). Big nodes represent the hBPIN hub proteins that
encoded by AD-related genes (degree .50). The black node border represents that the betweenness centrality of the protein is high (betweenness
centrality .561024). Functional interactions between protein Akt and the hub proteins CBP and p300 were highlighted as thick blue edges, which
were encoded by AKT1, CREBBP and EP300, respectively.
doi:10.1371/journal.pone.0085570.g008
Synergistic Neuroprotection by SAHA and Curcumin
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e85570
nated gene expression indicates persistent weakness in the
functional connection between the mentioned processes in AD
pathology. Thus, we proposed that functional restoration of the
link between the up- and down-regulated processes might greatly
benefit AD. Furthermore, by visualizing PPIs, we found that the
hub protein, Akt was located at the center of the network and
functionally interacted with CBP and p300 (Figure 8). The
corresponding genes CREBBP and EP300 were involved in the
two up-regulated processes, regulation of transcription and histone
acetylation. The AD-related gene AKT1 encodes protein Akt,
which was involved in all of the down-regulated processes except
endocytosis. Network analysis further revealed that due to the
synergistic activation of Akt activity with curcumin (Figure 4) and
inhibition of HDACs by SAHA [12] joint application of SAHA
and curcumin may restore the damaged functional link between
crucial disease-related processes in AD. Encoding hubs of high
betweenness centrality highlighted the important role of AD-
related genes CREBBP and EP300 (Figure 6b, 9) in the synergistic
protection against Ab25–35-mediated cell apoptosis.
Discussion
With aging of the population, neurological diseases such as AD
might make our health care system and even whole society
become overburdened in the near future [4]. Medicines for the
treatment of AD in today’s clinics are mainly acetylcholinesterase
inhibitors such as rivastigmine and the low-affinity NMDA
receptor antagonists such as memantine. Current medications
for symptomatic relief and the lack of effective control for disease
progression have made AD treatment strategy particularly
embarrassing, especially when facing the serious epidemiology of
AD [29]. Undoubtedly, the development and clinical accessibility
of effective AD pathology-reversing drugs is of urgent need to the
diagnosed and at risk AD patients.
Currently, among the potential pathological mechanisms and
intervention strategies that have been proposed as promising AD
treatments, tuning acetylation levels with HDAC inhibitors or
HAT activators is highlighted and widely recognized by research-
ers [10,14]. However, recent clinical failures of Ab-directed
therapeutics clearly remind us that there are more than one
molecular pathway simultaneously implicated in the complex
pathogenesis and development of AD [1]. Intervention of a single
pathological pathway may be not enough to effectively reverse or
slow down the disease’s progress due to the interaction of several
biological systems such as network robustness, redundancy,
crosstalk, et al. [30]. Thus, the simultaneous intervention of
multiple pathological pathways is a more preferable therapeutic
strategy especially for AD [31,32].
In this study, we demonstrated for the first time a potent
synergistic action of the anti-tumor HDAC inhibitor, SAHA, with
the natural flavonoid, curcumin, on Ab25–35-induced neuronal
injury in PC12 cells. No significant neuroprotection against Ab-
induced decrease of cell viability and apoptosis was found by using
1 mM of SAHA or 5 mM of curcumin alone. However, co-
Figure 9. Network visualization of potential mechanism underlying synergistic cytoprotection by SAHA and curcumin. SAHA is a
non-selective inhibitor of HDACs and along with curcumin synergistically activated Akt. Eight proteins encoded by AD-related genes were found to
be simultaneously associated with HDACs-encoding proteins (blue edges) and Akt which is encoded by AKT1 (green edges) in hBPIN. Nodes with
dark lines represent hubs of high betweenness centrality in hBPIN.
doi:10.1371/journal.pone.0085570.g009
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administration of SAHA and curcumin improved neuronal
viability and successfully restored the structural integrity of the
neuronal cells damaged by Ab treatment. Inhibition of HADC
activity and fine-tuning histone acetylation levels had been
previously shown to be the mechanisms underlying the role of
SAHA in AD [33]. Comparably, some molecular mechanisms
different from SAHAs are involved in the neuroprotective effect of
curcumin [34]. Thus, we proposed that the potent synergy
between SAHA and curcumin might not be through the same
molecular pathway but through the intrinsic linkage between two
independent mechanisms [15,35].
Recently, network biology, an emerging research branch of
systems biology, has been applied to re-define the neurological
diseases including AD from a biological network perspective [36–
38]. Here, a comprehensive network analysis of global gene
expression changes in AD [7] was performed in order to reveal the
causal links between pathological processes that promote AD
evolution. Among the identified AD-related genes that encoded
hubs in the hHPIN, the CBP/p300 signaling genes, CREBBP and
EP300, were both highlighted due to the stable correlation of their
expression with MMSE score and the square root of NFT score,
respectively. The influence of hub proteins over the PPIs in the
hHPIN strongly suggests that CBP/p300 signaling might not be
the only histone acetyltransferase and deacetylase balance that is
crucial for progressive neurodegeneration [14], but it may also be
implicated in the maintenance of normal neuronal functions [39].
Consistent with the previous finding [7], our result further
confirmed that significant alterations in expression of transcrip-
tional genes was associated with the onset of AD instead of those
genes that directly participated in the maintenance of cellular
energy supply and neuronal functions. This result supports the fact
that the available pharmaceutical therapies such as an acetylcho-
linesterase inhibitor and glutamate receptor antagonist can only
ameliorate cognition of AD patients but fail to reverse the AD
pathology [40]; while, the HDAC inhibitor, which affects
transcriptional activity, is able to enhance neuronal survival and
slow or prevent progressive neurodegeneration [33] and it has
beneficial effects on learning and memory [10]. We also
investigated the gene co-expression of all of the pathological
processes in AD and found that pathological processes would likely
co-alter as AD evolved, which partly hints that the two
participating processes need to be co-expressed to jointly fulfill
some cellular functions. For example, all of the up-regulated
pathological processes co-altered in gene expression due to the
demand of functional coordination. Although the down-regulated
pathological processes were relatively isolated for loss of direct
PPIs as GenePro analysis suggested, gene co-expression might still
reflect functional coordination between each other.
Uncoordinated gene co-expression of the important AD-related
processes regulation of transcription, protein transport and
regulation of protein ubiquitination during AD progress suggests
pathological weakening of the functional link between them [41].
Thus, restoration of the functional link between the above
pathological processes is very important for the reversal of AD
pathology. Critical PPIs were successfully revealed by establishing
a network visualization of functional links between processes.
Enhancing the activity of the CBP/p300 signaling pathway or Akt
should be equally reasonable for firming the association between
processes.
By targeting the CBP/p300 signaling pathway with small
molecule HADC inhibitors, one study showed that neuronal
survival could be enhanced and the progressive neurodegeneration
slowed or prevented and memory impairments could be reversed,
which is associated with the early-stage of AD [11]. However, our
experiment demonstrated that with the increase concentration of
SAHA, neuron cells might be subject to significant cytotoxicity.
This finding was consistent with the reasonable worries about the
specificity of this strategy [13]. However, we found that curcumin
could markedly improve the therapeutic specificity of SAHA via
synergistically relieving the Ab25–35-induced neuronal injury by
targeting Akt [34]. This is consistent with network analysis results
showing that the damaged functional link between Akt and CBP/
p300 pathways may play a causative role in the evolution of AD.
Our study proves that by representing the disease as a biological
process network can provide novel insights into the mechanism
underlying AD and facilitate identification of potential therapeutic
targets.
Taken together, our study suggests that the proposed synergistic
combination of SAHA and curcumin should be fully considered
for AD treatment in the future. More importantly, compared to a
monotherapy, a drug combination with synergistic action mech-
anisms would bring more advantages, such as being less prone to
drug resistance, more forcefully confrontational against biological
network robustness, smaller drug dose with less side effects, and
improved disease-relevant therapeutic effect and selectivity,
especially when complex pathological mechanisms are involved
in the progression of the disease [15,30,42]. Furthermore, instead
of a huge investment and the lengthy process in drug development,
rational utilization of the current drugs clinically available may be
a more economical strategy; thus, a viable therapeutic approach
could be proposed within a relatively short period of time. Further
functional experiments in vivo are definitely needed, especially,
regarding the therapeutic effect and safety between the novel
combination, SAHA and curcumin, for the treatment of AD.
In summary, the HADC inhibitor, SAHA, represents a hopeful
therapeutic agent for AD in the future. However, some technical
issues remain to be resolved; prominently, its poor therapeutic
selectivity due to its broad-spectrum inhibition of HDACs.
Because different molecular mechanisms are simultaneously
involved in the pathological complexity of AD, this leads to the
possibility and rationality of a potential drug combination therapy
by exerting a synergistic pharmacological effect. In this manner,
on one hand, the drug dose might be substantially reduced with
less drug side effects; on the other hand, the higher therapeutic
selectivity of medicine jointly used. Our in vitro experiment
confirmed an outstanding improvement of Ab-induced neuronal
injury by synergistic action of SAHA and the natural flavonoid,
curcumin. This finding strongly implies the feasibility of the non-
selective HADC inhibitor, SAHA, for clinical AD treatment in the
future, specifically as a novel means of SAHA-centered combina-
tion therapy with other drugs clinically available, such as
nutritional supplements with curcumin as the main ingredient.
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